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Purpose/Objective: Radiation-induced lung injury (RILI) is the most 
common side effect after radiation therapy for lung cancer. It is well 
known that the radiological finding of RILI is not always associated 
with the clinical manifestation of pneumonitis, and it is also not clear 
if it correlates with a decrease of patient's pulmonary function. In this 
study, we analyzed the predictive value of dosimetric parameters and 
Pulmonary Function Tests (PFTs), and their correlation with the 
radiological incidence of radiation-induced lung injury (RILI).  
Materials and Methods: Data from patients with non-small cell lung 
cancer (NSCLC), stage I-IIIB, treated with (chemo)-radiation in our 
Institution were analyzed. Eligibility criteria were: presence of visible 
tumor on a diagnostic chest CT scan, availability of CT scans before 
irradiation and at 3–6 months follow-up, baseline PFTs, with at least 
forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), 
total lung capacity (TLC), functional residual capacity (FRC) and vital 
capacity (VC) at 2–4 months follow-up. 
Results: Data from 68 patients treated from 2005 to 2012 were 
analyzed. The worsening of pulmonary function was evaluated 
comparing PFTs performed before and after radiotherapy. We tested 
the difference of percentage of predicted value of all the parameters 
and we obtained statistically significant results for Functional Residual 
Capacity (FRC), Total Lung Capacity (TLC), Vital Capacity (VC) and 
Functional Vital Capacity (FVC). Thirty-nine patients (57,4%) 
developed radiation-induced changes in lung tissue. Eighteen patients 
(26.6%) experienced a radiologically defined RILI associated to a 
worsening of respiratory performance. Nevertheless, these patients 
did not show the signs and symptoms of radiation pneumonitis, nor did 
their respiratory impairment interfere with the activities of daily 
living.  The remaining 19 patients (28.0%) had a post-treatment 
radiological diagnosis of RILI without any respiratory impairment 
during and/or post treatment. Two patients showed clinical signs of 
pneumonitis with only one of them experiencing a worsening of PFTs. 
Logistic regression was performed to verify whether the commonly 
used lung dosimetric constraints could be predictive of RILI. MLD was 
found to be the strongest predictor of RILI (Odds Ratio:1.19; 95% CI: 
1.04 – 1.35; p: 0.009), but even V20, V30, V5, ipsilateral V20 proved 
to be significantly related to the onset of RILI. 
  
 
 
 
Conclusions: Our study confirmed the important role of dosimetric 
parameters for the prediction of lung toxicity. It also proved that the 
radiological finding of RILI does not necessarily correlate with a 
worsening of the patient's respiratory performance, especially when 
treatment planning has been performed complying with the lung 
dosimetric constraints.  
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Purpose/Objective: Because small-cell lung cancer has a short 
doubling time, clinicians strive to obtain a diagnosis as soon as 
possible. We investigated the value of a short diagnostic process in a 
prospectively collected cohort of SCLC patients.  
Materials and Methods: Analysis of patients in our prospective 
database with stage I-III SCLC referred for concurrent chemo-
radiotherapy. Standard treatment was 45 Gy in 1.5 Gy fractions twice 
daily concurrently with carboplatin-etoposide, followed by 
prophylactic cranial irradiation (PCI) in case of non-progression. 
Survival was calculated from pathologic diagnosis (Kaplan-Meier 
method). Diagnostic delay was defined as the time between the first 
report of suspicious findings on imaging and the date of pathological 
verification of SCLC status. 
Results: 73 patients were included in the present analysis. Median 
overall survival was 20 months (95% CI 17.8-22.2 months), 2-year 
survival 38%. Median time between first imaging and pathology was 
19±64 days (range -1-505 days). Median time between pathology and 
start of chemotherapy was 13±10 days (range 0-47 days). In 
multivariate Cox regression analysis including WHO-PS, age, gender, 
LDH, PCI, SER, Gross Tumor Volume (GTV) and stage only the 
diagnostic delay significantly impacted overall survival (p=0.018). The 
hazard ratio for death per week delay was 1.04, amounting to a 
hazard ratio of 1.18 per month (28 days) delay. The time between 
pathology date and start of chemotherapy did not significantly impact 
overall survival in this cohort. 
Conclusions: In this series of stage I-III small cell lung cancer treated 
with concurrent chemo-radiation, diagnostic delay is an independent 
risk factor for stage I-III SCLC.  
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Purpose/Objective: Tumor behavior and treatment outcome of 
subgroups of non-small cell lung carcinoma (NSCLC) patients mainly 
depend on histology. In the present study, differences in glucose 
metabolism between adeno- and squamous cell NSCLCs were 
quantified using the hypoxia and glycolysis-related markers GLUT1, 
CAIX, MCT1, MCT4, vascular density, as well as 18FDG-PET imaging in 
curatively resected NSCLC patients. The relevance of these metabolic 
markers for disease-free survival (DFS) were analyzed. 
Materials and Methods: In 111 patients, pre-treatment 18FDG-uptake 
was quantified by calculating SUVmax and TLGmax. Metabolic marker 
expression, measured by immunofluorescent staining (protein) and 
qPCR (mRNA), and vascular density were determined in 90 fresh 
frozen resection specimens. Patients were retrospectively evaluated 
for DFS. 
Results: mRNA and protein expression of metabolic markers, with the 
exception of MCT4, and 18FDG-uptake were higher in squamous cell 
carcinomas than in adenocarcinomas, whereas adenocarcinomas were 
better vascularized. Adenocarcinomas had a worse DFS compared to 
squamous cell carcinomas (p=0.016) based on the potential to 
metastasize. High glucose consumption, as assessed by GLUT1 mRNA, 
SUVmax or TLGmax, was associated with a worse DFS in only 
adenocarcinomas.  
Conclusions: Our findings indicate that adenocarcinomas exhibit 
glycolysis under normoxic conditions close to the vessels, whereas 
squamous cell carcinomas are exposed to diffusion-limited hypoxia 
